Document is current
Any future updates will be listed below
-
Authors
Kettner, Nicole M.
Bui, Tuyen N.
Navarro-Yepes, Juliana
Ghotbaldini, Sanaz
Quintela, Bethanie
Luo, Catherine K.
Lam, Nghi
Rao, Xiayu
Raghavendra, Akshara Singareeka
Wang, Yan
Azizian, Nancy
Kris Eckols, T.
Kasembeli, Moses Makokha
Evans, Kurt
Yi, Min
Wingate, Hannah
Wang, Jing
Sahin, Aysegul A.
Meric-Bernstam, Funda
Hunt, Kelly K.
Damodaran, Senthil
Tweardy, David J.
Tripathy, Debu
Keyomarsi, Khandan
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (BC170615)
Cancer Prevention and Research Institute of Texas (RP170067, RP170067, RP170067, RP170067, RP180712, RP180712)
National Institutes of Health (CA255960)
- License Information
-
More Information
Article History
Received: 14 February 2025
Accepted: 3 July 2025
First Online: 25 July 2025
Competing interests
: F.M.-B.: AbbVie, Aduro BioTech, Aileron Therapeutics, Alkermes, AstraZeneca, Bayer Healthcare Pharmaceutical, Black Diamond, Biovica, Calithera Biosciences, Chugai Biopharmaceuticals.Curis, CytomX Therapeutics, Daiichi Sankyo, Debiopharm International, Ecor1 Capital, eFFECTOR Therapeutics, Eisai, European Organization for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), F.H.–La Roche, FogPharma, Genentech, GT Apeiron, Guardant Health, Harbinger Health, IBM Watson, Immunomedics, Infinity Pharmaceuticals, Inflection Biosciences, Jackson Laboratory, Karyopharm Therapeutics, Klus Pharma, Kolon Life Science, Lengo Therapeutics, Loxo Oncology, Menarini Group, Mersana Therapeutics, Novartis, OnCusp Therapeutics, OrigiMed, PACT Pharma, Parexel International, Pfizer, Protai Bio, Puma Biotechnology, Samsung Bioepis, Sanofi, Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, Taiho Pharmaceutical, Takeda Pharmaceutical, Tallac Therapeutics, Tyra Biosciences, Xencor, Zentalis, Zymeworks. K.K.H.: Armada Health, AstraZeneca, Cairn Surgical, Eli Lilly & Co, Lumicell. S.D.: EMD Serono, Guardant Health, Novartis, Pfizer, Sermonix, Taiho. D.J.T.: Tvardi Therapeutics. D.T.: AstraZeneca, GlaxoSmithKline, Gilead, Novartis, OncoPep, Pfizer, Polyphor, Personalis, Puma Biotechnology, Sermonix, Stemline-Menarini, Jazz Pharmaceuticals, AMBRX, BeiGene, Zetagen. K.K.: Apeiron, BluePrint, REPARE, Schrodinger, Novartis. The remaining authors declare no competing interests.
